Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Salomon Manier"'
Autor:
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Publikováno v:
Leukemia
Leukemia, 2022, 36 (4), pp.1066-1077. ⟨10.1038/s41375-021-01488-8⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2022, ⟨10.1038/s41375-021-01488-8⟩
Leukemia, 36(4), 1066-1077. Nature Publishing Group
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, no. 4, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, Van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Leukemia, 2022, 36 (4), pp.1066-1077. ⟨10.1038/s41375-021-01488-8⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2022, ⟨10.1038/s41375-021-01488-8⟩
Leukemia, 36(4), 1066-1077. Nature Publishing Group
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, no. 4, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, Van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a
Autor:
Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra, Rebecca Silbermann, Jing C. Ye, Gordon Cook, Robert F. Cornell, Sarah A. Holstein, Qian Shi, James Omel, Natalie S. Callander, Wee Joo Chng, Vania Hungria, Angelo Maiolino, Edward Stadtmauer, Sergio Giralt, Marcelo Pasquini, Andrzej J. Jakubowiak, Gareth J. Morgan, Amrita Krishnan, Graham H. Jackson, Mohamad Mohty, Maria Victoria Mateos, Meletious A. Dimopoulos, Thierry Facon, Andrew Spencer, Jesus San Miguel, Parameswaran Hari, Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva
Publikováno v:
Leukemia. 35(1)
Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity acros
Autor:
Salomon Manier, Carl Jannes Neuse, Mark Bustoros, Irene M. Ghobrial, Christoph Schliemann, Oliver Lomas, Yujia Shen
Publikováno v:
Leukemia. 34(11)
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM
Autor:
Andreas Petri, Yawara Kawano, Charlotte Albæk Thrue, Daisy Huynh, Sakari Kauppinen, Karma Salem, Katsutoshi Kokubun, Mahshid Rahmat, Marianne B. Løvendorf, Satoshi Takagi, Jihye Park, Kenichi Nagano, Shokichi Tsukamoto, Roland Baron, Salomon Manier, Oksana Zavidij, Michaela R. Reagan, Irene M. Ghobrial, Marzia Capelletti, Aldo M. Roccaro
Publikováno v:
Tsukamoto, S, Løvendorf, M B, Park, J, Salem, K Z, Reagan, M R, Manier, S, Zavidij, O, Rahmat, M, Huynh, D, Takagi, S, Kawano, Y, Kokubun, K, Thrue, C A, Nagano, K, Petri, A, Roccaro, A M, Capelletti, M, Baron, R, Kauppinen, S & Ghobrial, I M 2018, ' Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche ', Leukemia, vol. 32, no. 8, pp. 1739-1750 . https://doi.org/10.1038/s41375-018-0161-6
Myeloma bone disease is a devastating complication of multiple myeloma (MM) and is caused by dysregulation of bone remodeling processes in the bone marrow microenvironment. Previous studies showed that microRNA-138 (miR-138) is a negative regulator o
Autor:
Bruno Quesnel, Catherine Roche-Lestienne, Katarina K. Jovanović, Irene M. Ghobrial, Salomon Manier, Thierry Facon
Publikováno v:
Leukemia. 32:1295-1306
Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC l
Autor:
Aldo M. Roccaro, Siobhan Glavey, Antonio Sacco, John M. Asara, Michele Moschetta, Richard O. Hynes, Jihye Park, Karl R. Clauser, Antonio Palumbo, Yuji Mishima, Michael O'Dwyer, Alexandra Naba, Irene M. Ghobrial, Sabrin Tahri, Salomon Manier, Alberto Rocci, M. Gambella, Michaela R. Reagan
Publikováno v:
Leukemia. 31:2426-2434
The extracellular matrix (ECM) is a major component of the tumor microenvironment, contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In multiple myeloma (MM), interactions between MM cells and the bone ma
Autor:
Salomon Manier
Publikováno v:
Leukemia. 34:331-332
Autor:
Margaret Macro, Andrew Ar Belch, Antoine Tinel, Nathalie Meuleman, Jean Yves Mary, Christian Rose, Paula Rodriguez-Otero, Philippe Moreau, Wenming Chen, Michel Attal, Marie Lorraine Chretien, William Renwick, Kihyun Kim, Meletios A. Dimopoulos, Eileen M Boyle, Xavier Leleu, Michael Sturniolo, Thierry Facon, Heinz Ludwig, Mara Silvia Monzini, Vanessa Houck, Elena Zamagni, Adrian Tempescul, Salomon Manier, Cyrille Hulin, Shien Guo, Mohamad Mohty, Bruno M. Costa
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investi
Autor:
Angelo Vacca, Luis Palomera, Yawara Kawano, Irene M. Ghobrial, Marta Chesi, Antonio Sacco, Siobhan Glavey, Michele Moschetta, Ilyas Sahin, Felipe Prosper, Bruno Paiva, Leif Bergsagel, Matteo Bellone, Salomon Manier, Jiantao Shi, Yosra Aljawai, Michaela R. Reagan, Aldo M. Roccaro, Arianna Calcinotto, Yuji Mishima, C Unitt
Publikováno v:
Leukemia. 30:1103-1115
The role of endothelial progenitor cell (EPC)-mediated vasculogenesis in hematological malignancies is not well explored. Here, we showed that EPCs are mobilized from the bone marrow (BM) to the peripheral blood at early stages of multiple myeloma (M
Autor:
Alexandre Civet, Murielle Roussel, Michele Cavo, Meletios A. Dimopoulos, Angela Dispenzieri, Jae Hoon Lee, Michel Attal, Bruno M. Costa, Philippe Moreau, Eileen M Boyle, Philippe Rodon, Antoine Tinel, Yann Gaston-Mathé, Charles Dumontet, Jean Yves Mary, Thierry Facon, Juan José Lahuerta, Ann Van de Velde, Mohamad Mohty, Heinz Ludwig, Jan Van Droogenbroeck, Lugui Qiu, Aurore Perrot, Cyrille Hulin, Salomon Manier, Andrew Belch, Olivier Allangba
Publikováno v:
Leukemia
Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade >= 3 infection. The number of